cyclosporine ophthalmic
Orphan DrugFDA Approved
Description
Cyclosporine ophthalmic emulsion is a topical immunomodulator that increases tear production in patients with chronic dry eye and inflammatory ocular surface diseases. It is used off-label for severe vernal conjunctivitis when conventional therapies fail. The medication works by suppressing T-cell mediated inflammation in the conjunctiva and lacrimal glands.
Indications & Therapeutic Use
keratoconjunctivitis sicca, vernal keratoconjunctivitis, chronic dry eye disease
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
cyclosporine ophthalmic
| Generic Name | cyclosporine ophthalmic |
| Brands | 1 brand available |
| Active Ingredient | cyclosporine |
| Drug Class | keratoconjunctivitis sicca |
| Manufacturer | Allergan |
| Dosage Forms | ophthalmic emulsion 0.05%, 0.09% |
| Medical Code | S01XA18 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes